A clinical trial for 15 patients from the Bundang Cha Hospital research team
Confirmation of the effects of exercise such as preventing tremors in the hands and feet, no side effects
Patients who cannot move on their own can use public transport
Fetal brain stem cells have opened up a way to treat Parkinson’s disease.
CHA Hospital Bundang CHA (Director Sang-Wook Yoon) Department of Neurosurgery Professor Ju-Pyung Kim and Sang-Seob Jeong and Department of Bioengineering CHA University Professor Ji-Sook Moon Developed the world’s first dopamine neuronal precursor cells derived from bone- fetal midbrain tissue cells for Parkinson’s disease The results of clinical trials that improved the patient’s motor skills were published in the international journal Movement Disorders.
According to the study, 15 patients with Parkinson’s disease under the age of 70 were divided into 3 groups according to the dose of neural progenitor cells, and as a result, exercise capacity was restored in proportion to the dose. There were no side effects such as bleeding, immune rejection, inflammation, or tumor formation following treatment.
A clinical trial treating Parkinson’s disease with fetal stem cells was approved in Korea in 2013. At the time, the 65-year-old woman who underwent stem cell treatment for the first time in the world was having difficulty living on her own before donating stem cells, but now her athletic ability has improved enough to visit the hospital on public transport.
The research team succeeded in increasing the mass of dopaminergic neurons derived from the mid-fetal brain, solving ethical and technical limitations as fetal brain tissue is required.
This research was supported by the Biomedical Technology Development Project of the Korea National Research Institute funded by the Ministry of Science and ICT.
Copyright © Medical Tribune Unauthorized reproduction and redistribution prohibited
